Page 23 - Demo

Adjuvant pembrolizumab improves overall survival%u2022 Significant improvement in overall survival observed with pembrolizumab vs placebo %u2022 The estimated OS rate at 48 months was 91.2% with pembrolizumab and 86.0% with placebo. HR 0.6295% CI 0.44%u22120.87p = 0.005* Percentage of Participants100908070605040302010036 Mo 48 Mo98.093.9 89.5 86.098.6 96.3 93.9 91.212 Mo 24 Mo496 489 486 484 479 470 468 462 451 443 397 270 168 81 22 0498 494 487 483 476 463 455 441 433 423 382 248 155 79 22 0No. at RiskPembrolizumabPlacebo0 5 10 15 20 25 30 35 40 45 50 55 60 65 70 75Months23AKL* denotes statistical significanceCI, confidence interval; HR, hazard ratio; Mo, months; OS, overall survival. Choueiri et al. N Engl J Med 2024;390:1359-1371.